Literature DB >> 11074964

Xpose: a new device that provides reproducible and easy access for multivessel beating heart bypass grafting.

M K Dullum1, F G Resano.   

Abstract

BACKGROUND: Off-pump coronary artery bypass (OPCAB) is gaining acceptance and is now more widely used for coronary revascularization. Accessing the vessels, particularly on the lateral and inferior walls of the heart, can sometimes be challenging while the heart is beating. CASE REPORTS: The Xpose Access Device (Xpose; Guidant Corporation, Cupertino, Ca.) was used in 5 patients undergoing beating heart surgery to position the heart for coronary grafting. Hemodynamic and mixed venous oxygen saturation (MVO2) monitoring was performed with the device in place. In all cases, Xpose was successfully used to easily access and graft all of the target vessels including lateral and inferior wall vessels with the patients maintaining stable hemodynamic performance.
CONCLUSION: Xpose was used to successfully perform multivessel coronary bypass on all walls of the beating heart. These case reports suggest that use of the Xpose will facilitate and expand the ability to easily and consistently perform coronary artery bypass grafting on the beating heart.

Entities:  

Mesh:

Year:  2000        PMID: 11074964

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  3 in total

1.  Surgical Approaches to Coronary Artery Disease.

Authors:  Farzan Filsoufi; David H. Adams
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

2.  Innovative Surgical Strategies: Minimally Invasive CABG and Off-pump CABG.

Authors:  Afshin Ehsan; Prem Shekar; Sary Aranki
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-02

3.  Development and In Vitro Assessment of a Novel Vacuum-Based Tissue-Holding Device for Laparoscopic and Robotic Kidney Cancer Operations.

Authors:  Michael Gabi; Uwe Bieri; Venkat Ramakrishnan; Tilo Niemann; Antonio Nocito; Nadine Brader; Caroline Maake; Lukas John Hefermehl
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.